Chris Chamberlain has been head of Experimental Medicine and Diagnostics at UCB since 2013, with responsibility for ensuring the effective use of biomarkers and in vitro diagnostics across the UCB clinical portfolio. These efforts look to deliver both earliest proof of concept for investigational therapies and the appropriate use of molecular taxonomy and related mechanistic insights best to target such therapies in later development and use. Chris is a specialist registered physician and a chartered scientist within the UK and has extensive experience across the pharmaceutical industry, he has previously worked at SmithKline Beecham, Roche and AstraZeneca. Chris is Project co-coordinator for PRECISESADS, a large collaborative European study for the discovery of new molecular taxonomy in systemic auto-immune disease (www.precisesads.eu).
01-Feb-2017Profiling polyomics and prediction